Nkarta, Inc. (NKTX)
| Market Cap | 187.45M +51.8% |
| Revenue (ttm) | n/a |
| Net Income | -99.93M |
| EPS | -1.35 |
| Shares Out | 71.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 343,290 |
| Open | 2.710 |
| Previous Close | 2.740 |
| Day's Range | 2.580 - 2.730 |
| 52-Week Range | 1.630 - 3.650 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 11.20 (+327.48%) |
| Earnings Date | May 12, 2026 |
About NKTX
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $11.2, which is an increase of 327.48% from the latest price.
News
Nkarta Transcript: AGM 2026
The meeting covered director elections, ratification of the accounting firm, and executive compensation votes, with all proposals approved by stockholders. No additional proposals or questions were submitted, and a quorum was established with over 75% voting power represented.
Nkarta price target lowered to $9 from $25 at Evercore ISI
Evercore ISI lowered the firm’s price target on Nkarta (NKTX) to $9 from $25 and keeps an Outperform rating on the shares.
Nkarta reports Q1 EPS (37c), consensus (37c)
“Putting patients first and providing access to care in a familiar setting close to home matters” said Paul Hastings, CEO of Nkarta (NKTX). “In early April, we reached agreement with…
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings...
Nkarta Earnings release: Q1 2026
Nkarta released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Nkarta Quarterly report: Q1 2026
Nkarta has published its Q1 2026 quarterly earnings report on May 12, 2026.
Nkarta Slides: Corporate presentation
Nkarta has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Nkarta Proxy statement: Proxy filing
Nkarta filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Nkarta Proxy statement: Proxy filing
Nkarta filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials
Nkarta (NKTX) announced that it has reached agreement with the FDA on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed to alleviate the…
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted a strategic pivot to autoimmune diseases using off-the-shelf CAR-NK cell therapy, with a favorable safety profile and expanding outpatient access. Multiple indications are under study, with a data update and narrowed focus expected later this year. Cash runway extends into 2029.
Nkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea...
Nkarta price target lowered to $12 from $14 at Mizuho
Mizuho analyst Salim Syed lowered the firm’s price target on Nkarta (NKTX) to $12 from $14 and keeps an Outperform rating on the shares. The firm updated models in the…
Nkarta price target raised to $11 from $10 at Needham
Needham raised the firm’s price target on Nkarta (NKTX) to $11 from $10 and keeps a Buy rating on the shares.
Nkarta files $350M mixed securities shelf
17:24 EDT Nkarta (NKTX) files $350M mixed securities shelf
Nkarta reports Q4 EPS (37c), consensus (29c)
Nkarta (NKTX) had cash, cash equivalents, restricted cash, and investments in marketable securities of $295.1M as of December 31, 2025. “2025 was a year of strategic importance for Nkarta as…
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat au...
Nkarta Annual report: Q4 2025
Nkarta has published its Q4 2025 annual report on March 25, 2026.
Nkarta Earnings release: Q4 2025
Nkarta released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Nkarta Annual report: Q4 2025
Nkarta has published its Q4 2025 annual report on March 25, 2026.
Nkarta Registration statement: Registration filing
Nkarta filed a registration statement on March 25, 2026, providing details about a securities offering with the SEC.
Nkarta Transcript: Leerink Global Healthcare Conference 2026
The discussion highlighted a strategic pivot to autoimmune disease, focusing on CD19-targeted NK cell therapy with a strong safety profile and outpatient potential. Dose escalation and full lymphodepletion are central to achieving durable remissions, with upcoming data to guide indication selection and pivotal trial advancement.
Nkarta Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted ongoing clinical trials of off-the-shelf NK cell therapies for autoimmune diseases, emphasizing safety, accessibility, and the importance of deep B-cell depletion for durable remission. Data updates are expected this year, with strong financial runway supporting continued development.
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...